Effects of Cannabinoids on T-cell Function and Resistance to Infection

Journal of Neuroimmune Pharmacology

Volumn 10, Issue 2, 2015, Pages 204-216

  Eisenstein, Toby K ^a   Meissler, Joseph J ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CB2 agonist; Infection; T cells; 9 THC

Indexed keywords

CANNABINOID; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR; CANNABIS; DRONABINOL; IMMUNOSUPPRESSIVE AGENT;

APOPTOSIS; AUTOIMMUNE DISEASE; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RESISTANCE; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; AGONISTS; ANIMAL; ANTIBIOTIC RESISTANCE; AUTOIMMUNE DISEASES; DRUG EFFECTS; IMMUNOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; AUTOIMMUNE DISEASES; CANNABINOIDS; DRONABINOL; DRUG RESISTANCE, MICROBIAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECEPTOR, CANNABINOID, CB2; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84931005805     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-015-9603-3     Document Type: Review

References (87)

1. Akhmetshina A, Dees C, Busch N, Beer J, Sarter K, Zwerina J, Zimmer A, Distler O, Schett G, Distler JH (2009) The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 60:1129–1136
2. 9-tetrahydrocannabinol, cannabinol and cannabidiol on the immune system of mice. I. in vivo investigation of the primary and secondary immune response. Pharmacology 26:1–11
3. Basu S, Dittel BN (2011) Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res 51:26–38
4. Börner C, Höllt V, Kraus J (2007) Activation of human T cells induces upregulation of cannabinoid receptor type 1 transcription. Neuroimmunemodulation 14:281–286
5. Börner C, Smida M, Höllt V, Schraven B, Kraus J (2009) Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. J Biol Chem 284:35450–35460
6. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, Casellas P (1993) Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 214:173–180
7. 9-tetrahydrocannabinol in C57BL/6 mice. J Pharmacol Exp Ther 323:675–683
8. 9-tetrahydrocannabinol. J Leukoc Biol 83:785–796
9. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, Glass M (2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396:141–149
10. Cabral GA, Marciano-Cabral F (2004) Cannabinoid-mediated exacerbation of brain infection by opportunistic amebae. J Neuroimmunol 147:127–130
11. Cabral GA, Mishkin EM, Marciano-Cabral F, Coleman P, Harris L, Munson AE (1986) Effect of delta-9-tetrahydrocannabinol on herpes simplex virus type 2 vaginal infections in the guinea pig. Proc Soc Exp Biol Med 182:181–186
12. Castaneda JT, Harui A, Kiertscher SM, Roth JD, Roth MD (2013) Differential expression of intracellular and extracellular CB2 cannabinoid receptor protein by human peripheral blood leukocytes. J Neuroimm Pharmacol 8:323–332
13. Cencioni MT, Chiurchiu V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, Maccarrone M (2010) Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS ONE 5:e8688 [Electronic Resource]
14. Condie R, Herring A, Koh WS, Lee M, Kaminski NE (1996) Cannabinoid inhibition of adenlate cyclase-mediated signal transduction and IL-2 expression in the murine T-cell line, EL4.IL-2. J Biol Chem 271:13175–13183
15. Coopman K, Smith LD, Wright KL, Ward SG (2007) Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. Int Immunopharmacol 7:360–371
16. Costantino CM, Gupta A, Yewdall AW, Dale BM, Devi LA, Chen BK (2012) Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells. PLoS ONE 7:e33961 [Electronic Resource]
17. Croxford JL, Yamamura T (2005) Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol 166:3–18
18. Daaka Y, Friedman H, Klein TW (1996) Cannabinoid receptor proteins are increased in jurkat, human T-cell line after mitogen activation. J Pharmacol Exp Ther 276:776–783
19. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949
20. 9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. J Neuroimmunol 189:17–22
21. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443–450
22. Friedman H, Newton C, Klein TW (2003) Microbial infections, immunomodulation, and drugs of abuse. Clin Micro Rev 16:209–219
23. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54–61
24. Gardner B, Zu LX, Sharma S, Liu Q, Makriyannis A, Tashkin DP, Dubinett SM (2002) Autocrine and paracrine regulation of lymphcyte CB2 receptor expression by TGF-β. Biochem Biophys Res Comm 290:91–96
25. Ghosh S, Preet A, Groopman JE, Ganju RK (2006) Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol 43:2169–2179
26. Gorantla S, Makarov E, Roy D, Finke-Dwyer J, Murrin LC, Gendelman HE, Poluektova L (2010) Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS. J Neuroimmune Pharmacol 5:456–468
27. Hanuš L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E (1999) HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci 96:14228–14233. doi:10.1073/pnas.96.25.14228:
28. Hegde VL, Hegde S, Cravatt BF, Hofseth LJ, Nagarkatti M, Nagarkatti PS (2008) Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: Involvement of regulatory T cells. Mol Pharmacol 74:20–33
29. Huemer HP, Lassnig C, Bernhard D, Sturm S, Nowotny N, Kitchen M, Pavlic M (2011) Cannabinoids lead to enhanced virulence of the smallpox vaccine (vaccinia) virus. Immunobiology 216:670–677
30. Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, Martin BR, Bramblett RD, Reggio PH (1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 39:3875–3877
31. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR (1999) 3-(1′,1′-dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7:2905–2914
32. Kaminski NE (1996) Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression. Biochem Pharmacol 52:1133–1140
33. Kaminski NE, Abood ME, Kessler FK, Martin BR, Schatz AR (1992) Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 42:736–742
34. Karmaus PWF, Chen W, Crawford RB, Harkema JR, Kaplan BLF, Kaminski NE (2011) Deletion of cannabinoid receptors 1 and 2 exacerbates APC function to increase inflammation and cellular immunity during influenza infection. J Leukoc Biol 90:983–995
35. 9-tetrahydrocannabinol suppresses cytotoxic T lymphocyte function independent of CB1 and CB 2, disrupting early activation events. J Neuroimmune Pharmacol 7:843–855
36. Klein TW (2005) Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5:400–411
37. Klein TW, Newton CA, Widen R, Friedman H (1985) The effect of delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses. J Immunopharmacol 7:451–466
38. Klein TW, Kawakami Y, Newton C, Friedman H (1991) Marijuana components suppress inducion and cytolytic function of murine cytotoxic T-cells in vitro and in vivo. J Toxicol Environ Health 32:465–477
39. Klein TW, Friedman H, Specter S (1998) Marijuana, immunity and infection. J Neuroimmunol 83:102–115
40. 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-γ, IL-12 and IL-12 receptor β2 responses to legionella pneumophila infection. J Immunol 164:6461–6466
41. 9-tetrahydrocannabinol administration increases lymphocyte CXCR4 expression in rhesus macaques. J Neuroimmune Pharmacol 6:540–545
42. Lee SF, Newton C, Widen R, Friedman H, Klein TW (2001) Differential expression of cannabinoid CB2 receptor mRNA in mouse immune cells subpopulations and following B cell stimulation. Eur J Pharmacol 423:235–241
43. 9-tetrahydrocannabinol on in vitro sensitization of mouse splenic lymphocytes. Immunol Commun 7:557–566
44. 9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes. Int Immunopharmacol 1:699–712
45. Lombard C, Nagarkatti M, Nagarkatti P (2007) CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: Potential role for CB2-selective ligands as immunosuppressive agents. Clin Immunol 122:259–270
46. 9-tetrahydorcannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens. J Pharmacol Exp Ther 339:607–317
47. Lu H, Kaplan BL, Ngaotepprutaram T, Kaminski NE (2009) Suppression of T cell costimulator ICOS by Delta9-tetrahydrocannabinol. J Leukoc Biol 85:322–329
48. Luo YD, Patel MK, Wiederhold MD, Ou DW (1992) Effects of cannabinoids and cocaine on the mitogen-induced transformations of lymphocytes of human and mouse origins. Int J Immunopharmacol 14:49–56
49. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng X, Carrier EJ, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN (2007) Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 13:492–497
50. 9-tetrahydrocannabinol: functional and biochemical parameters. J Neuroimmunol 92:60–66
51. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564
52. 9-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther 302:451–465
53. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83–90
54. Mishkin EM, Cabral GA (1985) Delta-9-tetrahydrocannabinol decreases host resistance to herpes simplex virus type 2 vaginal infection in the B6C3F1 mouse. J Gen Virol 66:2539–2549
55. Molina PE, Amdee A, LeCapitaine NJ, Zabaleta J, Mohan M, Winsauer P, Stouwe CV (2011) Cannabinoid neuroimmune modulation of SIV disease. J Neuroimmune Pharmacol 6:516–527
56. Molina PE, Amedee AM, LeCapitaine NJ, Zabaleta J, Mohan M, Winsauer PJ, Stouwe CV, McGoey RR, Auten MW, LaMotte L, Chandra LC, Birke LL (2014) Modulation of gut-specific mechanisms by chronic D9-tetrahydrocannabinol administration in male rhesus macaques infected with simian immunodeficiency virus: a systems biology analysis. AIDS Res Hum Retrovir 30:567–578
57. Morahan PS, Klykken PC, Smith SH, Harris LS, Munson AE (1979) Effects of cannabinoids of host resistance to Listeria monocytogenes and herpes simples virus. Infect Immun 23:670–674
58. Munro S, Thomas KK, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65
59. Nakano Y, Pross S, Friedman H (1992) Contrasting effect of delta-9-tetrahydrocannabinol on IL-2 activity in spleen and lymph node cells of mice of different ages. Life Sci 52:41–51
60. Newton CA, Klein TW, Friedman H (1994) Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect Immun 62:4015–4020
61. Newton CA, Chou P, Perkins I, Klein TW (2009) CB1 and CB2 cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection. J Neuroimmune Pharmacol 4:92–102
62. 9-THC) of CD40 ligand (CD40L) expression in activated mouse splenic CD4+ T cells. J Neuroimmune Pharmacol 7:969–980
63. 9-tetrahydrocannabivarin. Br J Pharmacol 153:199–215
64. Pross SH, Klein TW, Newton CA, Smith J, Widen R, Friedman H (1990) Differential suppression of T-cell subpopulations by THC (delta-9-tetrahydrocannabinol). Int J Immunopharmacol 12:539–544
65. Purohit V, Rapaka RS, Rutter J (2014) Cannabinoid receptor-2 and HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol 9:447–453
66. Ramirez SH, Hasko J, Skuba A, Fan S, Dykstra H, McCormick R, Reichenbach N, Krizbai I, Mahedevan A, Zhang M, Tuma R, Son Y, Persidsky Y (2012) Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood–brain barrier dysfunction under inflammatory conditions. J Neurosci 32:4004–4016
67. Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P (2010) Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 215:598–605
68. Robinson RH,Meisser JJ, Breslow-Deckman JM,Gaughan J,AdlerMW, Eisenstein TK (2013) Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction. J Neuroimmune Pharmacol 8:1239–1250
69. Roth MD, Tashkin DP, Whittaker KM, Choi R, Baldwin GC (2005) Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse. Life Sci 77:1711–1722
70. Schatz AR, Koh WS, Kaminski NE (1993) Δ9-tetrahydrocannabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function. Immunopharmacology 26:129–137
71. Schwarz H, Blanco FJ, Lotz M (1994) Anandamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol 55:107–115
72. Servettaz A, Kavian N, Nicco C, Deveaux V, Chereau C, Wang A, Zimmer A, Lotersztajn S, Weill B, Batteux F (2010) Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am J Pathol 177:187–196
73. Singh UP, Singh NP, Singh B, Price RL, Nagarkatti M, Nagarkatti PS (2012) Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(−/−) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol 258:256–267
74. Smith SH, Harris LS, Uwayday IM, Munson AE (1978) Structure-activity relationships of natural and synthetic cannabinoids in suppression of humoral and cell-mediated immunity. J Pharmacol Exp Ther 207:165–170
75. Specter S, Lancz G, Westrich G, Friedman H (1991) Delta-9-tetrahydrocannabinol augments murine retroviral induced immunosuppression and infection. Int J Immunopharmacol 13:411–417
76. 9-tetrahydrocannabinol. J Leukoc Biol 84:1574–1584
77. 2) protects against experimental colitis. Inflamm Bowel Dis 15:1678–1685
78. 9-tetrahydrocannabinol and ethanol. Toxicol Appl Pharmacol 71:1–13
79. 9-THC) in rhesus macaques infected with simian immunodeficiency virus. Exp Clin Psychopharmacol 19:154–172
80. Xu H, Cheng CL, Chen M, Manivannan A, Cabay L, Pertwee RG, Coutts A, Forrester JV (2007) Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol 82:532–541
81. 9-tetrahydrocannabinol-mediated alterations in antigen-specific T cell responses. J Biol Chem 289:18707–18718
82. 9-tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 133:124–131
83. Zhang M, Adler MW, Abood ME, Ganea D, Jallo J, Tuma RF (2009a) CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvasc Res 78:86–94
84. Zhang M, Martin BR, Adler MW, Razdan RJ, Kong W, Ganea D, Tuma RF (2009b) Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimmune Pharmacol 4:249–259
85. 9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of bcl-2 and capsase-1. J Pharmacol Exp Ther 286:1103–1109
86. 9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165:373–380
87. Ziring D, Wei B, Velazquez P, Schrage M, Buckley NE, Braun J (2006) Formation of B and T cell subsets require the cannabinoid receptor CB2. Immunogenetics 58:714–725